84 Pages | 13 Exhibits | 2014 Analysis | Forecasts Through 2018 Product Family: Market Reports

In the United States (U.S.), serious ophthalmic disease affects more than 35 million. This number is expected to significantly increase due to the aging of the population and disorders such as diabetes that may result in progressive vision loss. Alarmingly, the number of patients with cataracts is expected to increase significantly over the next decade, contributing a substantial increase in the number of cataract surgeries.

The development of new, minimally invasive energy-based (laser/phacoemulsification or "phaco") technologies is providing safe and effective, medically necessary, vision-saving treatment to millions of patients, particularly those with cataracts who also seek vision correction surgery. Meanwhile, non-medically necessary, high-cost refractive surgery, such as laser in situ keratomileusis (LASIK) vision correction, continues to increase despite several setbacks.

Overall, more than an estimated 5.5 million directed-energy based (laser/phaco) ophthalmic procedures, including cataract laser surgery, diabetic retinopathy laser surgery, glaucoma/laser trabeculoplasty and laser-based vision correction surgery, were estimated to have been performed in the U.S. in 2013. The advancement of safer and more cost-effective laser-based technologies, such as femtosecond laser cataract surgery and other technological improvements, are expected to improve patient outcomes and drive ophthalmic surgical procedures and market growth over the next half-decade.

For the purposes of this report, the U.S. market for ophthalmic surgical systems includes sales derived from laser and phaco systems for vision correction and the minimally invasive treatment of cataracts, glaucoma, retinal, and other ophthalmic disorders. In addition to ophthalmic surgical systems sales, the market forecast includes revenues derived from surgical accessories/instruments and disposables utilized in minimally invasive directed energy-based ophthalmic surgery. In 2013, the U.S. ophthalmic surgical systems market was valued at approximately $1,695.8 million. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2,256.4 million in the year 2018.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. ophthalmic surgical systems market. Covered topics in this report include an overview of common ophthalmic diseases/disorders and therapies; U.S. procedure volumes; laser/phaco/energy-based surgical systems, next-generation laser-based systems and emerging technologies; and company profiles.


i. Clinical Overview
	a. Age-Related Macular Degeneration
	b. Cataracts
	c. Diabetic Retinopathy
	d. Glaucoma
	e. Refractive Errors
ii. Market
iii. Methodology


1.1 Clinical Overview
	1.1.1 Age-Related Macular Degeneration
	1.1.2 Cataracts
	1.1.3 Diabetic Retinopathy
	1.1.4 Glaucoma
	1.1.5 Refractive Errors
1.2 Ophthalmic Procedures
	1.2.1 Age-Related Macular Degeneration	Anti-Angiogenic Therapy	Verteporfin Photodynamic Therapy	Transpupillary Thermotherapy	Retinal Photocoagulation 
	1.2.2 Cataract Surgery	Capsulotomy	Procedure Volumes Forecast
	1.2.3 Diabetic Retinopathy Laser Surgery	Procedure Volumes Forecast
	1.2.4 Glaucoma-Laser Trabeculoplasty	Procedure Volumes Forecast
	1.2.5 Refractive Surgery	Laser-Based Vision Correction	Photorefractive Keratectomy	Laser In Situ Keratomileusis	Laser Epithelial Keratomileusis	Photoablative Inlay Laser In Situ Keratomileusis	Procedure Volumes Forecast
1.3 Market Analysis
	1.3.1 Market Forecast
1.4 Competitive Analysis
	1.4.1 Market Share

Exhibit 1-1: 2013, Estimated U.S. Prevalence of Selected  Ophthalmic Conditions
Exhibit 1-2: Laser Therapy for Age-Related Macular Degeneration, U.S. Procedure Volumes Forecast, 2011-2018
Exhibit 1-3: Cataract Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
Exhibit 1-4: Diabetic Retinopathy Laser Surgery, U.S. Procedure  Volumes Forecast, 2011-2018 (in Thousands)
Exhibit 1-5: Glaucoma Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
Exhibit 1-6: Refractive Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)
Exhibit 1-7: Selected Market Drivers and Limiters
Exhibit 1-8: U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018
Exhibit 1-9: 2013, U.S. Ophthalmic Surgical Systems Market,  Estimated Percentage of Sales, by Application
Exhibit 1-10: 2013, Leading Competitors in the U.S. Ophthalmic Surgical Systems Market and Applications for Leading Products
Exhibit 1-11: 2013, U.S. Ophthalmic Surgical Systems Market,  Share by Supplier


2.1 Abbott Laboratories
	2.1.1 Background
	2.1.2 Abbott Medical Optics Division
	2.1.3 Acquisitions
	2.1.4 Surgical Systems
	2.1.5 Medical Optics Revenues
	2.1.6 Selected Financials
2.2 Carl Zeiss Meditec AG
	2.2.1 Background
	2.2.2 Carl Zeiss Ophthalmology Business
	2.2.3 Acquisitions
	2.2.4 Surgical Systems
	2.2.5 Ophthalmology Segment Revenues
	2.2.6 Selected Financials
2.3 IRIDEX Corporation
	2.3.1 Background
	2.3.2 Acquisitions/Divestitures
	2.3.3 Surgical Systems
	2.3.4 Selected Financials
2.4 Lumenis Ltd.
	2.4.1 Background
	2.4.2 Ophthalmic Division
	2.4.3 Surgical Systems
	2.4.4 Ophthalmic Division Revenues
	2.4.5 Selected Financials
2.5 Novartis
	2.5.1 Background
	2.5.2 Alcon Division
	2.5.3 Acquisitions
	2.5.4 Surgical Systems
	2.5.5 Alcon Division Revenues
	2.5.6 Selected Financials
2.6 Valeant Pharmaceuticals
	2.6.1 Background
	2.6.2 Bausch and Lomb
	2.6.3 Acquisitions
	2.6.4 Surgical Systems
	2.6.5 Bausch + Lomb Revenues
	2.6.6 Selected Financials


  1. Abbott Laboratories
  2. Abbott Medical Optics
  3. Alcon
  4. Allergan, Inc.
  5. ARC Laser GmbH
  6. Bausch + Lomb, Inc.
  7. Carl Zeiss Meditec AG
  8. Ellex Medical Pty. Ltd, Inc.
  9. IRIDEX Corporation
  10. LENSAR, Inc.
  11. Lightmed Corporation
  12. Lumenis, Ltd.
  13. Novartis
Contact Us

Need help finding medtech research? Let us help you!